Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection

AIDS

Volumn 25, Issue 7, 2011, Pages 967-975

  Thorpe, Julia ^a   Saeed, Sahar ^a   Moodie, Erica E M ^b   Klein, Marina B ^a,c  

^a Royal Victoria Hospital   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

antiretroviral treatment interruption; co infection; hepatitis C virus; HIV; liver fibrosis

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SUPERINFECTION; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CANADA; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 79954865473     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283455e4b     Document Type: Article

References (43)

1. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schech-ter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-665. (Pubitemid 29149796)
2. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected in-dividuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685-692. (Pubitemid 46568625)
3. WeberR,SabinCA, Friis-Moller N, Reiss P, El-SadrWM, KirkO, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
4. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19:2117-212 5. (Pubitemid 41669000)
5. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183:134-137. (Pubitemid 32043052)
6. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
7. Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-OrengoJF, et al. Slower fibrosis progres-sion in HIV/HCV-coinfected patients with successful HIV sup-pression usingantiretroviral therapy.JHepatol2006; 44:47-55. (Pubitemid 41772515)
8. Fuster D, Planas R, Muga R, Ballesteros AL, SantosJ, TorJ, et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:1293-1297. (Pubitemid 40065924)
9. Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, Lopez-Cortes LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immuno-deficiency virus/hepatitis C virus. Hepatology 2009; 50:1056-1063.
10. Vella S. Structured treatment interruptions and treatment intensification. AIDS Clin Care 2000; 12:55-57; 62.
11. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treat-ment failure. AIDS 2000; 14:2857-2867. (Pubitemid 32042749)
12. Hirschel B. Planned interruptionsof anti-HIVtreatment. Lancet Infect Dis 2001; 1:53-59.
13. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of anti-retroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
14. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interrup-tion strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981 1989. (Pubitemid 43867699)
15. Fox Z, PhillipsA, Cohen C, Neuhaus J, Baxter J, Emery S, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive nonnucleoside reverse trans-criptase inhibitor-based regimen. AIDS 2008; 22:2279 2289.
16. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21:169-178. (Pubitemid 46036924)
17. Leon A, Martinez E, MilinkovicA, Mora B, MallolasJ, BlancoJL, et al. Influence of repeated cycles of structured therapy inter-ruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. J Antimicrob Che-mother 2009; 63:184-188.
18. Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005; CD005482.
19. Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One 2008; 3:e2021.
20. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C AIDS 2009; 23:71-82.
21. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
22. Tedaldi E, Peters L, NeuhausJ, Puoti M, RockstrohJ, Klein MB, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47:1468-1475.
23. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40:538-544. (Pubitemid 41669157)
24. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6:375-378. (Pubitemid 41723304)
25. Lefkowitch JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res 2007; 38:634-643. (Pubitemid 47001563)
26. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrso-poulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
27. Klein MB, SaeedS, Yang H, CohenJ, Conway B, CooperC, et al. Cohort profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2010; 39:1162-1169.
28. Bacchetti P, Tien PC, Seaberg EC, O'Brien TR, Augenbraun MH, Kral AH, et al. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007; 7:145.
29. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Predictionof hepaticfibrosisin HIV/HCVco-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43:78-84. (Pubitemid 40805276)
30. Wai CT, GreensonJK, Fontana RJ, Kalbfleisch JD, MarreroJA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 2003; 38:518-526. (Pubitemid 36919874)
31. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560. (Pubitemid 30660034)
32. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561 570. (Pubitemid 30660035)
33. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9:1501-1515.
34. Moore DM, Zhang W, Yip B, Genebat M, Lima VD, Montaner JS, et al. Nonmedically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med 2010; 11:299-307.
35. Peters L for the INSIGHT SMART Study Group. Biomarkers of inflammation and coagulation and risk of non-AIDS death in HIV/hepatitis co-infected patients in the SMART study [abstract 660]. In: 17th conference on retroviruses and opportunistic infections; February 2010; San Francisco, USA.
36. Madge S, Mocroft A, Wilson D, Youle M, Lipman MC, Phillips A, et al. Participation inclinicalstudiesamongpatientsinfected with HIV-1 inasingletreatmentcentreover 12 years. HIVMed 2000; 1:212-218.
37. Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 2006; 42:554-561. (Pubitemid 44162423)
38. D'arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, et al. Interruption of highly active anti-retroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Im-mune Defic Syndr 2005; 38:407-416. (Pubitemid 40381550)
39. Li X, Margolick JB, Conover CS, Badri S, Riddler SA, Witt MD, et al. Interruption and discontinuation of highly active anti-retroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2005; 38:320-328. (Pubitemid 40333499)
40. Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, et al. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. J Acquir Immune Defic Syndr 2009; 52:531-537.
41. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C J Antimicrob Chemother 2010; 65:543-547.
42. Peters L, Mocroft A, Soriano V, Rockstroh J, Ledergerber B, Karlsson A, et al., the EuroSIDA Study Group. Hyaluronic acid as a prognostic marker of hepatic coma and liver-related death in HIV/viral hepatitis co-infected patients [abstract 821]. In: 16th conference on retroviruses and opportunistic infections; February 2009; Montreal.
43. Sanchez-CondeM, Montes-Ramirez ML, MirallesP, AlvarezJM, Bellon JM, Ramirez M, et al. Comparison of transient elasto-graphy and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17:280-286.